<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>“Alzheimer为Business开放了：”有争议的FDA批准可以为未来的药物铺平道路 
				“Alzheimer’s is open for business:” Controversial FDA approval could pave the way for future drugs			</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script>
<script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">
				“Alzheimer’s is open for business:” Controversial FDA approval could pave the way for future drugs			<br/>“Alzheimer为Business开放了：”有争议的FDA批准可以为未来的药物铺平道路 </h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2021-06-10 05:13:05</div><div class="story_img_container"><a href="http://img2.diglog.com/img/2021/6/925bc851d4b518eb407ec7e4b89737d8.png"><img src="http://img2.diglog.com/img/2021/6/925bc851d4b518eb407ec7e4b89737d8.png" class="img-fluid my_story_img" onerror="this.style.display='none'"></a></div><div class="page_narrow text-break page_content"><p>In a nutshell, the approval of Aduhelm came after conflicting results from clinical trials. In   November 2020  an independent FDA advisory board did not recommend that the agency endorse the drug, but in June, the agency approved the drug anyway via an Accelerated Approval Program.</p><p>简而言之，Aduhelm的批准在临床试验的突破性结果之后来了。 2020年11月，一个独立的FDA咨询委员会不建议该机构赞同该药物，但在6月份，该机构无论如何都通过加速批准计划批准该药物。</p><p> Aduhelm is now the first novel treatment to address one underlying cause of Alzheimer’s – beta-amyloid plaques that accumulate in the brain.</p><p> Aduhelm现在是第一部分新的治疗方法，以解决积累在大脑中的阿尔茨海默氏症 - β-淀粉样蛋白斑块的一个潜在原因。</p><p>  The drug received support from   patient and industry groups  (the FDA also   noted  that the “need for treatment is urgent”, in a statement explaining the agency’s choice). Still, there have been a number of doctors who have expressed concern. One member of the expert committee that voted not to recommend the approval of Aduhelm back in November has   resigned  since the announcement.</p><p>  药物接受了患者和行业团体的支持（FDA还指出，“治疗需要迫切需要”，在解释该机构的选择）。尽管如此，还有许多人表示关注的医生。专家委员会的一名成员，不要建议11月份批准阿布尔姆的批准自公告以来辞职。</p><p> However, the inconsistency of the science and highly public debate around the approval of Aduhelm doesn’t seem to have halted enthusiasm within the pharmaceutical industry. Rather, it may signal a new wave of additional treatments in the next few years, which will piggyback off of the approval of Aduhelm (however controversial that approval may be).</p><p> 然而，科学和高度公众辩论的不一致似乎在Aduhelm的批准中似乎在制药行业中似乎没有停止热情。相反，它可能会在未来几年内发出新的额外治疗浪潮，这将捎带ADUHELM的批准（但是批准可能是有争议的）。</p><p> “This is great news for investors and for drug companies that are working towards new drugs,” says   Alison Ward , a research scientist at the USC Schaeffer Center for Health Policy and Economics.</p><p> “这是投资者和正在努力新毒品的药物公司的好消息，”USC Schaeffer卫生政策和经济学中心的研究科学家艾莉森病区“</p><p> Historically there have been a few factors that have made the development of a drug for Alzheimer’s an uphill battle.</p><p> 从历史上看，有一些因素已经为阿尔茨海默氏症的艰难战斗制定了一种药物。</p><p> The first, is a 17-year history of failure to bring a drug through clinical trials. Even Biogen’s clinical trials for Aduhelm were halted in 2019 because it wasn’t clear that they would reach their clinical endpoints (effectively, the target outcomes of the trial). In fact, Aduhlem was approved based on a “surrogate endpoint,” the decline of beta-amyloid, not the primary endpoint, cognitive function.</p><p> 首先，是17年历史未能通过临床试验带来药物。即使是Biogen的Aduhelm的临床试验在2019年停止，因为他们不明确表示他们将达到其临床终点（有效地，试验的目标结果）。事实上，Aduhlem是基于“替代终点”批准的β-淀粉样蛋白的衰落，而不是主要终点，认知功能。 </p><p> Trials for Alzheimer’s drugs have also historically been expensive. A 2018 paper in   Alzheimer’s and Dementia: Translational Research and Clinical Interventions  (a journal run by the Alzheimer’s Association)  estimated that the cost of developing an Alzheimer’s drug was about   $5.6 billion . By comparison, the mean investment needed to bring a new drug to market is about   $1.3 billion  according to analysis of SEC filings for companies that applied for FDA approval between 2009 and 2018 (though the median cost was about $985 million). Older estimates have put the costs of bringing a drug to market at   $2.8 billion .</p><p>阿尔茨海默氏药物的试验也历史上也很贵。 Alzheimer和Dementia的2018篇论文：翻译研究和临床干预（由阿尔茨海默氏症协会的杂志）估计，发展阿尔茨海默氏药物的成本约为56亿美元。相比之下，根据申请2009年至2018年期间申请FDA批准的公司的分析，将新药物送到市场所需的平均投资约为13亿美元（虽然中位数成本约为9.85亿美元）。较老的估算使得将药物带到28亿美元的销售费用。</p><p> For Alzheimer’s specifically, Phase 3 trials are still largely sponsored by industry, but over the past five years, trials sponsored solely by the industry have   decreased . Government grants and funding via public-private partnerships have made up an i  ncreasing share  of available funds.</p><p> 对于阿尔茨海默氏症的特别是，第3阶段试验仍然主要由行业赞助，但在过去的五年中，完全由行业赞助的审判减少了。通过公私合作伙伴关系的政府补助和资助已弥补了可用资金的份额。</p><p> Martin Tolar, the founder CEO of   Alzheon , another company pursuing an oral treatment for Alzheimer’s (currently in a phase 3 clinical trial), says that attracting other forms of funding was a challenge.</p><p> Alzheon的创始人COO Martin Tolar是阿尔茨海默氏症（目前在第3期临床试验）的另一家公司（目前在一期临床试验）中，表示吸引了其他形式的资金是一项挑战。</p><p>  “It was impossible to finance anything,” he says. “It was impossible to get Wall Street interested because everything was failing one after the other after the other.”</p><p>  “不可能融资任何东西，”他说。 “不可能让华尔街感兴趣，因为一切都在另一个之后失败了。”</p><p> He expects this recent approval of Aduhelm to change that outlook considerably. Already, we are seeing some increased interest in companies already in phase 3 clinical trials: After the FDA announcement,   shares of Eli Lilly , also running a phase 3 clinical trial,   surged by 10 percent .</p><p> 他预计最近批准的Aduhelm将大大改变展望。我们已经看到，我们已经看到了已经在第3阶段临床试验中增加的兴趣：在FDA公告之后，Eli Lilly股份，也运行了3期临床试验，飙升了10％。</p><p> “I’ve had probably hundreds of discussions, of calls, from bankers, investors, collaborators, pharma, you name it,” Tolar says. “Alzheimer’s is open for business.”</p><p> “我可能有数百种讨论，来自银行家，投资者，合作者，Pharma，你称之为它，”Tolar说。 “阿尔茨海默尔为企业开放。”</p><p> With renewed interest and what appears like a pathway to approval at the FDA, the environment for the next generation of Alzheimer’s drugs seems to be ripening. Right now, there are about   130  phase 3 clinical trials on Alzheimer’s drugs that are either completed, active or recruiting.</p><p> 随着更新的兴趣，看起来像在FDA批准的途径，下一代阿尔茨海默氏药的环境似乎已经成熟。目前，在阿尔茨海默氏症的药物上有大约130期临床试验，这些药物是完成，积极或招募的。 </p><p> Tolar sees the FDA decision, based on imperfect data, as a “signal of urgency” to approve new treatments that are imminent arrivals.</p><p>Tolar基于不完美的数据，将FDA决定视为批准即将抵达的新治疗的“紧迫性”。</p><p> As Ward pointed out in a   white paper  on in-class drug innovation, “follow on” drugs go on to become leaders in the industry, especially if they demonstrate better safety or efficacy than the drug that was first to market.  That, the paper argues, suggests drug approval may “pave the way” for more effective drugs in the future.</p><p> 随着病房在一篇白皮书中指出课堂上的药物创新，“追随”药物继续成为该行业的领导者，特别是如果他们表现出比首次上市的药物更好的安全性或效力。这篇论文认为，毒品批准可能会在未来为更有效的毒品“铺平”。</p><p> In the case of Alzheimer’s, it might not be one drug that dominates, even as more get approved, she notes. Rather, a cadre of new, approved drugs may go on to compliment one another.</p><p> 在Alzheimer的情况下，它可能不是一个占主导地位的药物，即使越来越多获得批准，她还指出。相反，一个新的新的批准药物可能继续互相恭维。</p><p> “The way that the medical community is thinking of AD [Alzheimer’s Disease] now is that it’s likely going to be a combination of drugs or a cocktail of drugs that comes together to have true success at delaying progression,” she says.</p><p> “医学界正在思考AD [Alzheimer疾病的方式]现在是毒品或鸡尾酒的组合可能会在延迟进展时具有真正的成功，”她说。</p><p> “If we’re looking to treat AD with a cocktail of drugs, history suggests it’s individually approved drugs that come together to make those drug cocktails.”</p><p> “如果我们希望用鸡尾酒对待广告，历史表明它是一个单独批准的药物，以制作那些药物鸡尾酒。”</p><p> There are still some potential pitfalls for future drugs to consider.   One argument is  that with an approved drug available, it may be more difficult to recruit participants in clinical trials, slowing the pace of drug discovery. In that respect, Ward argues that this will ultimately be dwarfed by patients who will now look into a potential diagnosis for Alzheimer’s now that there’s something to treat it with.</p><p> 未来药物仍有一些潜在的陷阱需要考虑。一项论点是，通过可获得批准的药物，招聘参与者在临床试验中可能更加困难，减缓药物发现的步伐。在这方面，Ward认为，这将由现在患有对阿尔茨海默氏症的潜在诊断的患者令人沮丧，现在有一些东西可以与之治疗。</p><p> There’s also the fact that Aduhelm’s costs are high (about   $56,000  for a year’s supply, the brunt of which will be   borne by Medicare ), and the data remains questionable. Those factors may push patients towards other drugs, even if they’re in clinical trials.</p><p> 还有情况下，Aduhelm的成本很高（每年供应的约56,000美元，那么由Medicare承担的，数据库），数据仍然是可疑的。这些因素可能会将患者推向其他药物，即使他们在临床试验中。 </p><p> Additionally, there is the question of how well Aduhelm actually performs during the critical followup study mandated by the FDA as a condition of the drug’s approval. Whether Aduhelm can truly slow cognitive decline, as well as help address levels of beta-amyloid from the brain, remains questionable based on current data.</p><p>此外，在FDA授权的批判性后续研究中，还存在如何在FDA授权的批判性后续研究中进行的问题。 AduhelM是否可以真正缓慢认知的下降，以及从大脑的β-淀粉样蛋白的解决水平，基于当前数据仍然可疑。</p><p> Still, Tolar doesn’t see the results of that study as particularly relevant because the industry will have moved on. Biogen CEO Michel Vounatsos has said it may not share results of this trial for as many as   nine years , though he noted the company would try to deliver data sooner.</p><p> 尽管如此，TOLAR仍然没有看到该研究的结果，因为该行业将继续下载。 Biogen Ceo Michel Vountsos表示，这可能不会与此审判的结果分享多达9年，但他指出，该公司将尽快提供数据。</p><p>  Tolar’s phase 3 clinical trial just began dosing this week, and is scheduled to   end by 2024 .</p><p>  Tolar的第3期临床试验刚刚开始在本周加油，并计划到2024年结束。</p><p> Biogen and Esai will likely   also  have another drug ready for evaluation by then, as two phase 3 clinical trials for another beta-amyloid antibody treatment called lecanemab are scheduled for completion   by 2024  and   2027 .</p><p> 生物原性和欧安组织可能还有另一种药物可以通过另一种准备评价的药物，因为调度称为lecanemab的另一种β-淀粉样蛋白抗体治疗的3阶段3临床试验预先完成2024和2027。</p><p> The signal sent by Monday’s approval may be a pathway for future drugs, rather than an end itself. The data is imperfect, the costs high, and the controversy considerable, but the band-aid has been ripped off.</p><p> 星期一批准发出的信号可能是未来药物的途径，而不是最终本身。数据不完美，成本高，争议很大，但救济援助已被剥夺。 </p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://techcrunch.com/2021/06/09/alzheimers-is-open-for-business-controversial-fda-approval-could-pave-the-way-for-future-drugs/">https://techcrunch.com/2021/06/09/alzheimers-is-open-for-business-controversial-fda-approval-could-pave-the-way-for-future-drugs/</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/business/">#business</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/open/">#open</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/药物/">#药物</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/恶搞/">#恶搞</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/qq/">#qq</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/谷歌/">#谷歌</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/工具/">#工具</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy;2012-2021 diglog.com </div></div></body></html>